المؤلفون: Blanes, Margarita, González, José D., Lahuerta, Juan J., Ribas, Paz, Lorenzo, Ignacio, Boluda, Blanca, Sanz, Miguel A., de la Rubia, Javier

المصدر: Leukemia & Lymphoma; Feb2015, Vol. 56 Issue 2, p415-419, 5p

مصطلحات موضوعية: MULTIPLE myeloma treatment, STEM cell transplantation, AUTOTRANSPLANTATION, BORTEZOMIB, BUSULFAN, MELPHALAN

مستخلص: A bortezomib-containing regimen followed by high-dose therapy and autologous stem cell transplant (ASCT) is considered the standard of care for front-line therapy in younger patients with newly diagnosed multiple myeloma (MM). We analyzed the results of ASCT with an intravenous busulfan 9.6 mg/kg and melphalan 140 mg/m² (ivBUMEL) preparative regimen in 47 patients with newly diagnosed MM who had received bortezomib-based combinations as pre-transplant induction. The overall response rate and complete response after transplant were 100% and 49%, respectively. With a median follow-up of 24.5 months, median overall survival and progression-free survival have not been reached. Mucositis and febrile neutropenia were the most frequent toxicities observed. No case of sinusoidal obstruction syndrome was observed and there was no transplant-related mortality. These results suggest that front-line induction therapy with a bortezomib-based combination followed by ASCT with ivBUMEL is an effective and well-tolerated therapeutic approach for transplant eligible patients with MM. [ABSTRACT FROM AUTHOR]

: Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Puig, Noemí¹ (AUTHOR), De La Rubia, Javier¹ (AUTHOR), Remigia, María J.¹ (AUTHOR), Jarque, Isidro¹ (AUTHOR), Martín, Guillermo¹ (AUTHOR), Cupelli, Luca¹ (AUTHOR), Sanz, Guillermo F.¹ (AUTHOR), Lorenzo, Ignacio¹ (AUTHOR), Sanz, Jaime¹ (AUTHOR), Martínez, Jesús A.¹ (AUTHOR), Jiménez, Carmen¹ (AUTHOR), Sanz, Miguel A.¹ (AUTHOR) msanz@uv.es

المصدر: Leukemia & Lymphoma. Aug2006, Vol. 47 Issue 8, p1488-1494. 7p. 3 Charts, 2 Graphs.

مصطلحات موضوعية: *LYMPHOCYTIC leukemia, *AUTOTRANSPLANTATION, *TRANSPLANTATION of organs, tissues, etc., *MORTALITY, *CONDITIONED response

مستخلص: CBV and BEAM are the two most frequently used regimens for patients with lymphoma undergoing autologous hematopoietic stem-cell transplantation (ASCT). This study compared their morbidity and transplant-related mortality (TRM) in 113 patients with non-Hodgkin's lymphoma (69) and Hodgkin's disease (44) undergoing ASCT between 1990 – 2004. CBV (cyclophosphamide, 6000 mg m -2 ; VP-16, 750 mg m -2 ; and high-dose BCNU, 800 mg m -2 ) was administered to 75 patients and 38 received BEAM (BCNU, 300 mg m -2 ; VP-16, 800 mg m -2 ; cytarabine, 800 mg m -2 ; melphalan, 140 mg m -2 ). Patients in the BEAM group had a significantly higher median age ( p = 0.002) and were more heavily treated before ASCT ( p = 0.003). More patients showed active disease at transplant in the BEAM group ( p = 0.04). Sinusoidal obstruction syndrome (SOS) was more frequent in the CBV group (11% vs 0%, p = 0.048). There were 20 (18%) transplant-related deaths, 18 in the CBV and two in the BEAM group. Infectious complications (12 patients, seven with pneumonia) and SOS (four) were the most frequent causes of death. The cumulative incidences of TRM were 25% in the CBV and 7% in the BEAM group ( p = 0.02). CBV thus produced a higher incidence of SOS and TRM than BEAM in this series. [ABSTRACT FROM AUTHOR]

المؤلفون: Lahuerta, Juan José, Grande, Carlos, Blade, Joan, Martínez-López, Joaquín, De La Serna, Javier, Alegre, Adrian, Laraña, José García, Caballero, Dolores, De La Rubia, Javier, Marín, Julián, Perez-Lopez, Cristina, Sureda, Anna, Escudero, Antonio, Cabrera, Rafael, Conde, Eulogio, García-Ruiz, Juan Carlos, Pérez-Equiza, Katty, Hernandez, Fernando, Palomera, Luis

المصدر: Leukemia & Lymphoma; Jan2002, Vol. 43 Issue 1, p67, 8p, 7 Charts, 4 Graphs

مصطلحات موضوعية: AUTOTRANSPLANTATION, MULTIPLE myeloma, CHI-squared test

مصطلحات جغرافية: SPAIN

مستخلص: Examines the efficacy of autologous stem cell transplantation (ASCT) for multiple myeloma in Spain. Factors contributing to the efficacy of ASCT; Comparison of responses with chi-square test results; Differences in leukocyte graft parameters.

المؤلفون: de la Rubia, Javier^1,2 delarubia_jav.@gva.es

المصدر: Brazilian Journal of Hematology & Hemotherapy / Revista Brasileira de Hematologia e Hemoterapia. 2014, Vol. 36 Issue 2, p96-97. 2p.

مصطلحات موضوعية: *MULTIPLE myeloma, *AUTOTRANSPLANTATION, *HEALTH outcome assessment

مستخلص: The author comments on the significant change of the multiple myeloma (MM) autologous transplantation which results to better understanding of improved supportive care, disease biology, and effective treatment.